Tae Seung Lee, Young Hoon Choi, Jun Yeol Kim, Myeong Hwan Lee, Kyu-Hyun Paik, In Rae Cho, Woo Il Kwon, Sang Hyub Lee, In Seok Lee, Myung Ah Lee, Jin-Young Jang, Ji Kon Ryu, Yong-Tae Kim, Woo Hyun Paik
{"title":"5-氟尿嘧啶/亚叶酸素与卡培他滨辅助治疗胆道癌的比较。","authors":"Tae Seung Lee, Young Hoon Choi, Jun Yeol Kim, Myeong Hwan Lee, Kyu-Hyun Paik, In Rae Cho, Woo Il Kwon, Sang Hyub Lee, In Seok Lee, Myung Ah Lee, Jin-Young Jang, Ji Kon Ryu, Yong-Tae Kim, Woo Hyun Paik","doi":"10.1111/jgh.17044","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5-fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence-free survival, overall survival, and adverse events were investigated between the two groups.</p><p><strong>Results: </strong>Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence-free survival and overall survival did not show statistically significant differences between the capecitabine and FL groups. After propensity score matching, the capecitabine group showed significantly longer overall survival (median, NA [52 - NA] vs. 43 months [32 - NA], p = 0.032). Although severe adverse events did not differ between both groups (29.4% vs. 20.2%, p = 0.135), overall adverse events, including anemia, thrombocytopenia, hand-foot syndrome, and skin color change, were significantly more frequent in the capecitabine group (90.6% vs. 57.9%, p < 0.001). After propensity score matching, severe adverse events (30.3% vs. 14.5%, p = 0.032) and overall adverse events (90.8% vs. 65.8%, p < 0.001) were significantly more frequent in the capecitabine group.</p><p><strong>Conclusion: </strong>In patients with curatively resected BTC, capecitabine demonstrated superior efficacy in prolonging overall survival, whereas FL had a more favorable safety profile with fewer adverse events.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of 5-Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer.\",\"authors\":\"Tae Seung Lee, Young Hoon Choi, Jun Yeol Kim, Myeong Hwan Lee, Kyu-Hyun Paik, In Rae Cho, Woo Il Kwon, Sang Hyub Lee, In Seok Lee, Myung Ah Lee, Jin-Young Jang, Ji Kon Ryu, Yong-Tae Kim, Woo Hyun Paik\",\"doi\":\"10.1111/jgh.17044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5-fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence-free survival, overall survival, and adverse events were investigated between the two groups.</p><p><strong>Results: </strong>Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence-free survival and overall survival did not show statistically significant differences between the capecitabine and FL groups. After propensity score matching, the capecitabine group showed significantly longer overall survival (median, NA [52 - NA] vs. 43 months [32 - NA], p = 0.032). Although severe adverse events did not differ between both groups (29.4% vs. 20.2%, p = 0.135), overall adverse events, including anemia, thrombocytopenia, hand-foot syndrome, and skin color change, were significantly more frequent in the capecitabine group (90.6% vs. 57.9%, p < 0.001). After propensity score matching, severe adverse events (30.3% vs. 14.5%, p = 0.032) and overall adverse events (90.8% vs. 65.8%, p < 0.001) were significantly more frequent in the capecitabine group.</p><p><strong>Conclusion: </strong>In patients with curatively resected BTC, capecitabine demonstrated superior efficacy in prolonging overall survival, whereas FL had a more favorable safety profile with fewer adverse events.</p>\",\"PeriodicalId\":15877,\"journal\":{\"name\":\"Journal of Gastroenterology and Hepatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastroenterology and Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/jgh.17044\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jgh.17044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:胆道癌(BTC)预后差,即使在根治性切除后复发率仍然很高。本研究旨在比较卡培他滨和5-氟尿嘧啶/亚叶酸素(FL)作为BTC患者根治性切除后辅助治疗的疗效和安全性。方法:回顾性分析2011年至2023年间行根治性手术切除和辅助化疗的BTC(包括胆囊、肝外和肝内胆管癌)患者的医疗记录。比较两组患者的无复发生存期、总生存期和不良事件。结果:263例患者中,85例接受卡培他滨治疗,178例接受FL治疗。卡培他滨组和FL组的无复发生存期和总生存期无统计学差异。倾向评分匹配后,卡培他滨组总生存期明显延长(中位NA [52 - NA] vs. 43个月[32 - NA], p = 0.032)。尽管严重不良事件在两组之间没有差异(29.4%对20.2%,p = 0.135),但总体不良事件,包括贫血、血小板减少症、手足综合征和肤色改变,在卡培他滨组明显更频繁(90.6%对57.9%,p结论:在治疗性切除BTC患者中,卡培他滨在延长总生存期方面表现出卓越的疗效,而FL具有更有利的安全性,不良事件较少。
Comparison of 5-Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer.
Background: The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5-fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.
Methods: We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence-free survival, overall survival, and adverse events were investigated between the two groups.
Results: Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence-free survival and overall survival did not show statistically significant differences between the capecitabine and FL groups. After propensity score matching, the capecitabine group showed significantly longer overall survival (median, NA [52 - NA] vs. 43 months [32 - NA], p = 0.032). Although severe adverse events did not differ between both groups (29.4% vs. 20.2%, p = 0.135), overall adverse events, including anemia, thrombocytopenia, hand-foot syndrome, and skin color change, were significantly more frequent in the capecitabine group (90.6% vs. 57.9%, p < 0.001). After propensity score matching, severe adverse events (30.3% vs. 14.5%, p = 0.032) and overall adverse events (90.8% vs. 65.8%, p < 0.001) were significantly more frequent in the capecitabine group.
Conclusion: In patients with curatively resected BTC, capecitabine demonstrated superior efficacy in prolonging overall survival, whereas FL had a more favorable safety profile with fewer adverse events.
期刊介绍:
Journal of Gastroenterology and Hepatology is produced 12 times per year and publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatology, gastroenterology and endoscopy. Papers cover the medical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas. All submitted papers are reviewed by at least two referees expert in the field of the submitted paper.